oxycodonhydrochlorid "g.l." 5 mg filmovertrukne tabletter
g.l. pharma gmbh - oxycodonhydrochlorid - filmovertrukne tabletter - 5 mg
oxycodonhydrochlorid "orion" 10 mg/ml injektions-/infusionsvæske, opløsning
orion corporation - oxycodonhydrochlorid - injektions-/infusionsvæske, opløsning - 10 mg/ml
ambroxolhydrochlorid "unither pharmaceuticals" 6 mg/ml oral opløsning
unither pharmaceuticals - ambroxolhydrochlorid - oral opløsning - 6 mg/ml
ambroxolhydrochlorid "unither pharmaceuticals" 30 mg oral opløsning i brev
unither pharmaceuticals - ambroxolhydrochlorid - oral opløsning i brev - 30 mg
natriumklorid-glucose "braun" 4,5 mg/ml + 25 mg/ml infusionsvæske, isotonisk
b. braun melsungen - glucosemonohydrat, natriumchlorid - infusionsvæske, isotonisk - 4,5 mg/ml + 25 mg/ml
sevelamerhydrochlorid "waymade" 400 mg filmovertrukne tabletter
waymade b.v. - sevelamerhydrochlorid - filmovertrukne tabletter - 400 mg
kaliumklorid "b.braun" 1 mmol/ml koncentrat til infusionsvæske, opløsning
b. braun melsungen - kaliumchlorid - koncentrat til infusionsvæske, opløsning - 1 mmol/ml
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidbilleddannelse - terapeutiske radioaktive lægemidler - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.